Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05831124
Other study ID # C4941001
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date April 19, 2023
Est. completion date July 15, 2024

Study information

Verified date April 2024
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to learn about a pneumococcal vaccine with a new ingredient (PF-07872411) intended to enhance the effects of the vaccine. This pneumococcal vaccine with the new ingredient may prevent the diseases caused by pneumococcal bacteria like meningitis, sepsis, ear infections and sinusitis. Meningitis is an infection in which the tissue around the brain and spine is swollen. Sepsis is a very serious infection in your blood caused by a germ (a bacteria). Sinusitis is when your sinuses (the air-filled spaces inside your nose and head), are infected. This study is seeking for healthy participants who: - are above 50 years of age and less than 64 years of age. - have not taken any vaccine for pneumococcal diseases before. - have not taken any vaccines with additional ingredients within 1 year before administration of the study vaccine. All participants will receive a single study vaccine shot in the upper arm muscle at the study clinic. The study will compare the experiences of people receiving the vaccine with a new ingredient in the vaccine to those without the new ingredient. This will be done by comparing 2 different dose levels of the new ingredient. It will also be compared against people who receive the vaccine without the new ingredient and at different dose levels. This will help the study team establish if the vaccine with a new ingredient is safe and effective. Participants will take part in this study for about 12 months. During this time participants will have up to 6 clinic visits. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these visits. Some participants will need to have blood taken for laboratory tests before they can be judged to be eligible to be included in the study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date July 15, 2024
Est. primary completion date July 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 64 Years
Eligibility Inclusion Criteria: - Male or female participants =50 and =64 years of age at the time of consent. - Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including those with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease, within 6 months before receipt of study intervention. - Female participants of childbearing potential or male participants able to father children and who are willing to use acceptable methods of contraception for at least 28 days after the last dose of study intervention; or female participants not of childbearing potential; or male participants not able to father children. Exclusion Criteria: - History of a severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component in pneumococcal conjugate vaccines and any other diphtheria toxoid-containing vaccine. - Serious chronic disorder, including history of metastatic malignancy, severe COPD requiring supplemental oxygen, end-stage renal disease with or without dialysis, cirrhosis of the liver, clinically unstable cardiac disease, or any other disorder, that in the investigator's opinion, would make the participant inappropriate for entry into the study. - History of microbiologically proven invasive disease caused by S pneumoniae. - Current febrile illness (body temperature =100.4°F [=38.0°C]) or other acute illness within 48 hours before study intervention administration. - Pregnant female participants or breastfeeding female participants (known or suspected). - Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation. - Receipt of any inactivated or otherwise nonlive vaccine within 14 days or any live vaccine within 28 days before administration of study intervention. - Receipt of an adjuvanted vaccine containing QS-21 (or similar saponin adjuvant), MPL, or MF59 within 1 year before administration of study intervention

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Low dose multivalent pneumococcal conjugate vaccine formulation A
Biological
Low dose multivalent pneumococcal conjugate vaccine formulation B
Biological
Biological:
Low dose of multivalent pneumococcal conjugate vaccine control
low dose multivalent pneumococcal conjugate vaccine
Standard dose multivalent pneumococcal conjugate vaccine control
multivalent pneumococcal conjugate vaccine

Locations

Country Name City State
United States Centennial Medical Group Columbia Maryland
United States Centennial Medical Group Elkridge Maryland
United States Indago Research & Health Center, Inc Hialeah Florida
United States Research Centers of America ( Hollywood ) Hollywood Florida
United States Velocity Clinical Research, Omaha Omaha Nebraska
United States Rochester Clinical Research, LLC Rochester New York
United States Clinical Trials of Texas, LLC San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of participants reporting local reactions within 7 days after vaccination Local reactions (redness, swelling, pain at the injection site) after vaccination. 7 days
Primary Percentage of participants reporting systemic events within 7 days after vaccination Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain, and joint pain) after vaccination. 7 days
Primary Percentage of participants reporting Adverse Events (AEs) within 1 month after vaccination Adverse Events occurring within 1 month after vaccination. 1 month
Primary Percentage of participants reporting Serious Adverse Events (SAEs) within 6 months after vaccination SAEs occurring within 6 months after vaccination. 6 months
Primary Percentage of participants reporting Serious Adverse Events (SAEs) withing 12 months after vaccination SAEs occurring within 12 months after vaccination. 12 months
Primary Percentage of participants reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) within 6 months after vaccination NDCMCs occurring within 6 months after vaccination. 6 months
Primary Percentage of participants reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) withing 12 months after vaccination NDCMCs occurring within 12 months after vaccination. 12 months
Primary Percentage of participants reporting Medically Attended Adverse Events (MAAEs) within 6 months after vaccination MAAEs occurring within 6 months after vaccination. 6 months
Primary Percentage of participants reporting Medically Attended Adverse Events (MAAEs) within 12 months after vaccination MAAEs occurring within 12 months after vaccination. 12 months
Primary Stage 1 and Stage 2 Only - Percentage of participants with abnormal hematology and chemistry laboratory values 2 weeks after vaccination Abnormal hematology and chemistry laboratory values occurring 2 weeks after vaccination. 2 weeks
Secondary Pneumococcal opsonophagocytic activity (OPA) titers OPA geometric mean titers (GMTs) 1 month after vaccination 1 month
See also
  Status Clinical Trial Phase
Completed NCT04546425 - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants Phase 3
Recruiting NCT06044077 - A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People Phase 3
Completed NCT02146365 - Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
Completed NCT04525599 - A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator Phase 1
Active, not recruiting NCT05512819 - A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan Phase 3
Completed NCT04530838 - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants Phase 3
Active, not recruiting NCT06026748 - A Phase I Study of XJ103 in Chinese Healthy Subjects Phase 1
Completed NCT04526574 - Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age Phase 3
Completed NCT05329259 - A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India Phase 4
Completed NCT00234338 - Study Evaluating Prevenar in High-Risk Children N/A
Completed NCT01767402 - Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults Phase 1
Active, not recruiting NCT05569954 - Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) Phase 3
Completed NCT01111214 - Child Pneumococcal Serotype Epidemiology In Greece N/A
Completed NCT01298544 - A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers Phase 4
Completed NCT04830358 - Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults Phase 1
Completed NCT04379713 - 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants Phase 3
Completed NCT04887948 - Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 Phase 3
Completed NCT04382326 - 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants Phase 3
Not yet recruiting NCT00843895 - Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years N/A
Completed NCT01734239 - A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018) Phase 3